Bank of New York Mellon Corp Sells 5,282 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Bank of New York Mellon Corp lessened its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 115,779 shares of the biopharmaceutical company’s stock after selling 5,282 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.24% of Theravance Biopharma worth $1,089,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its holdings in shares of Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock valued at $2,462,000 after purchasing an additional 143,781 shares in the last quarter. JPMorgan Chase & Co. increased its position in Theravance Biopharma by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company’s stock worth $2,151,000 after buying an additional 7,620 shares during the last quarter. Jane Street Group LLC raised its holdings in Theravance Biopharma by 1.1% during the third quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock valued at $1,165,000 after buying an additional 1,640 shares in the last quarter. Algert Global LLC acquired a new stake in shares of Theravance Biopharma in the third quarter worth about $851,000. Finally, PDT Partners LLC boosted its stake in shares of Theravance Biopharma by 31.2% during the 3rd quarter. PDT Partners LLC now owns 87,177 shares of the biopharmaceutical company’s stock worth $703,000 after acquiring an additional 20,738 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Price Performance

Shares of TBPH opened at $9.39 on Tuesday. The company has a market capitalization of $464.53 million, a PE ratio of -9.30 and a beta of 0.15. Theravance Biopharma, Inc. has a one year low of $7.44 and a one year high of $10.90. The company’s fifty day moving average price is $9.34 and its 200 day moving average price is $9.07.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The business had revenue of $18.75 million during the quarter, compared to the consensus estimate of $29.90 million. Analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares in the company, valued at $2,786,085. This trade represents a 1.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 6.90% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.